Daily analyst calls. One clear view.
Search published Canadian and U.S. analyst updates by company, firm and action.
November 18, 2026
Canada: 24 calls U.S.: 259 calls
283 calls shown
| Company / Ticker | Market | Analyst firm | Action | Previous rating | Rating | Previous target | New target | Source |
|---|---|---|---|---|---|---|---|---|
| AbbVieABBV | U.S. | Piper Sandler | Maintains | — | Overweight | — | US$349.00 | ReportDetailsAbbVie (ABBV) — Piper Sandler reiterated its Overweight rating with a price target of $349.00. Report title |
| AbCellera BiologicsABCL | U.S. | Lake Street Capital | Initiates | — | Buy | — | US$19.00 | ReportDetailsAbCellera Biologics (ABCL) — Lake Street Capital initiated coverage with a Buy rating and a price target of $19.00. Report title |
| ACADIA PharmaceuticalsACAD | U.S. | Oppenheimer | Target Down | — | Market Perform | US$23.00 | US$21.00 | ReportDetailsACADIA Pharmaceuticals (ACAD) — Oppenheimer lowered its price target from $23.00 to $21.00, maintaining a Market Perform rating. Report title |
| AdeiaADEA | U.S. | Rosenblatt Securities | Maintains | — | Buy | — | US$35.00 | ReportDetailsAdeia (ADEA) — Rosenblatt Securities reiterated its Buy rating with a price target of $35.00. Report title |
| Adherex TechnologiesFENC | U.S. | HC Wainwright | Target Up | — | Buy | US$16.00 | US$17.00 | ReportDetailsAdherex Technologies (FENC) — HC Wainwright raised its price target from $16.00 to $17.00, maintaining a Buy rating. Report title |
| AECOMACM | U.S. | Barclays | Target Up | — | Equal Weight | US$73.00 | US$90.00 | ReportDetailsAECOM (ACM) — Barclays raised its price target from $73.00 to $90.00, maintaining an Equal Weight rating. Report title |
| AECOMACM | U.S. | KeyCorp | Target Up | — | Overweight | US$78.00 | US$97.00 | ReportDetailsAECOM (ACM) — KeyCorp raised its price target from $78.00 to $97.00, maintaining an Overweight rating. Report title |
| Affiliated Managers GroupAMG | U.S. | TD Cowen | Maintains | — | Buy | — | US$583.00 | ReportDetailsAffiliated Managers Group (AMG) — TD Cowen reiterated its Buy rating with a price target of $583.00. Report title |
| Aldebaran Resources Inc.ALDE:CA | Canada | National Bank | Maintains | — | Outperform | — | C$5.00 | ReportDetailsAldebaran Resources Inc. (ALDE:CA) — National Bank maintained an Outperform rating with a price target of C$5.00. Report title |
| Alnylam PharmaceuticalsALNY | U.S. | JPMorgan Chase & Co. | Maintains | — | — | — | US$254.00 | ReportDetailsAlnylam Pharmaceuticals (ALNY) — JPMorgan Chase & Co. reiterated its price target with a price target of $254.00. Report title |
| Alnylam PharmaceuticalsALNY | U.S. | Rodman & Renshaw | Downgrade | — | Neutral | — | — | ReportDetailsAlnylam Pharmaceuticals (ALNY) — Rodman & Renshaw downgraded the stock to Neutral. Report title |
| Amer SportsAS | U.S. | Cantor Fitzgerald | Target Up | — | Overweight | US$46.00 | US$47.00 | ReportDetailsAmer Sports (AS) — Cantor Fitzgerald raised its price target from $46.00 to $47.00, maintaining an Overweight rating. Report title |
| Amer SportsAS | U.S. | UBS Group | Target Down | — | Buy | US$62.00 | US$56.00 | ReportDetailsAmer Sports (AS) — UBS Group lowered its price target from $62.00 to $56.00, maintaining a Buy rating. Report title |
| American Axle & ManufacturingDCH | U.S. | Morgan Stanley | Target Down | — | Equal Weight | US$7.00 | US$6.00 | ReportDetailsAmerican Axle & Manufacturing (DCH) — Morgan Stanley lowered its price target from $7.00 to $6.00, maintaining an Equal Weight rating. Report title |
| American Axle & ManufacturingDCH | U.S. | TD Cowen | Maintains | — | Buy | — | US$10.00 | ReportDetailsAmerican Axle & Manufacturing (DCH) — TD Cowen reiterated its Buy rating with a price target of $10.00. Report title |
| Antero ResourcesAR | U.S. | Morgan Stanley | Target Up | — | Overweight | US$51.00 | US$52.00 | ReportDetailsAntero Resources (AR) — Morgan Stanley raised its price target from $51.00 to $52.00, maintaining an Overweight rating. Report title |
| APA CorporationAPA | U.S. | Morgan Stanley | Target Up | — | Underweight | US$43.00 | US$44.00 | ReportDetailsAPA Corporation (APA) — Morgan Stanley raised its price target from $43.00 to $44.00, maintaining an Underweight rating. Report title |
| AppLovinAPP | U.S. | JPMorgan Chase & Co. | Maintains | — | — | — | US$400.00 | ReportDetailsAppLovin (APP) — JPMorgan Chase & Co. reiterated its price target with a price target of $400.00. Report title |
| Atrium Mortgage Investment CorporationAI:CA | Canada | Fundamental Research | Maintains | — | Buy | — | C$12.49 | ReportDetailsAtrium Mortgage Investment Corporation (AI:CA) — Fundamental Research maintained a Buy rating with a price target of C$12.49. Report title |
| BaiduBIDU | U.S. | Barclays | Target Down | — | Equal Weight | US$80.00 | US$72.00 | ReportDetailsBaidu (BIDU) — Barclays lowered its price target from $80.00 to $72.00, maintaining an Equal Weight rating. Report title |
| BaiduBIDU | U.S. | Stifel Nicolaus | Maintains | — | — | — | US$83.00 | ReportDetailsBaidu (BIDU) — Stifel Nicolaus reiterated its price target with a price target of $83.00. Report title |
| BaiduBIDU | U.S. | Susquehanna | Target Down | — | Neutral | US$105.00 | US$75.00 | ReportDetailsBaidu (BIDU) — Susquehanna lowered its price target from $105.00 to $75.00, maintaining a Neutral rating. Report title |
| Bally'sBALY | U.S. | Truist Financial | Target Down | — | Hold | US$10.00 | US$9.00 | ReportDetailsBally's (BALY) — Truist Financial lowered its price target from $10.00 to $9.00, maintaining a Hold rating. Report title |
| BILL Holdings, Inc.BILL | U.S. | BMO Capital Markets | Target Up | — | Market Perform | US$56.00 | US$68.00 | ReportDetailsBILL Holdings, Inc. (BILL) — BMO Capital Markets raised its price target from $56.00 to $68.00, maintaining a Market Perform rating. Report title |
| BiogenBIIB | U.S. | Needham & Company LLC | Maintains | — | Buy | — | — | ReportDetailsBiogen (BIIB) — Needham & Company LLC reiterated its Buy rating. Report title |
| Bitdeer Technologies GroupBTDR | U.S. | StoneX | Target Down | — | Buy | US$22.00 | US$15.00 | ReportDetailsBitdeer Technologies Group (BTDR) — StoneX lowered its price target from $22.00 to $15.00, maintaining a Buy rating. Report title |
| Black Diamond Group Ltd.BDI:CA | Canada | Canaccord Genuity | Maintains | — | Buy | — | C$26.00 | ReportDetailsBlack Diamond Group Ltd. (BDI:CA) — Canaccord Genuity maintained a Buy rating with a price target of C$26.00. Report title |
| BlackLineBL | U.S. | BMO Capital Markets | Target Down | — | Market Perform | US$32.00 | US$30.00 | ReportDetailsBlackLine (BL) — BMO Capital Markets lowered its price target from $32.00 to $30.00, maintaining a Market Perform rating. Report title |
| Bridger Aerospace GroupBAER | U.S. | Canaccord Genuity Group | Downgrade | Buy | Hold | — | US$1.00 | ReportDetailsBridger Aerospace Group (BAER) — Canaccord Genuity Group downgraded the stock from Buy to Hold, with a price target of $1.00. Report title |
| Bridger Aerospace GroupBAER | U.S. | Stifel Nicolaus | Downgrade | Buy | Hold | — | US$0.25 | ReportDetailsBridger Aerospace Group (BAER) — Stifel Nicolaus downgraded the stock from Buy to Hold, with a price target of $0.25. Report title |
| BrightSpring Health ServicesBTSG | U.S. | BMO Capital Markets | Target Up | — | Outperform | US$80.00 | US$84.00 | ReportDetailsBrightSpring Health Services (BTSG) — BMO Capital Markets raised its price target from $80.00 to $84.00, maintaining an Outperform rating. Report title |
| BrookfieldBN | U.S. | Morgan Stanley | Target Down | — | Overweight | US$54.00 | US$52.00 | ReportDetailsBrookfield (BN) — Morgan Stanley lowered its price target from $54.00 to $52.00, maintaining an Overweight rating. Report title |
| Brookfield Asset ManagementBAM | U.S. | Morgan Stanley | Target Up | — | Equal Weight | US$54.00 | US$57.00 | ReportDetailsBrookfield Asset Management (BAM) — Morgan Stanley raised its price target from $54.00 to $57.00, maintaining an Equal Weight rating. Report title |
| Builders FirstSourceBLDR | U.S. | Royal Bank Of Canada | Maintains | — | Sector Perform | — | US$56.00 | ReportDetailsBuilders FirstSource (BLDR) — Royal Bank Of Canada reiterated its Sector Perform rating with a price target of $56.00. Report title |
| BWX TechnologiesBWXT | U.S. | TD Cowen | Target Down | — | Buy | US$230.00 | US$180.00 | ReportDetailsBWX Technologies (BWXT) — TD Cowen lowered its price target from $230.00 to $180.00, maintaining a Buy rating. Report title |
| CalumetCLMT | U.S. | TD Cowen | Target Down | — | Hold | US$40.00 | US$37.00 | ReportDetailsCalumet (CLMT) — TD Cowen lowered its price target from $40.00 to $37.00, maintaining a Hold rating. Report title |
| CamtekCAMT | U.S. | Northland Capital | Upgrade | Market Perform | Outperform | — | US$130.00 | ReportDetailsCamtek (CAMT) — Northland Capital upgraded the stock from Market Perform to Outperform, with a price target of $130. Report title |
| CamtekCAMT | U.S. | Northland Securities | Upgrade | Market Perform | Outperform | — | US$130.00 | ReportDetailsCamtek (CAMT) — Northland Securities upgraded the stock from Market Perform to Outperform, with a price target of $130.00. Report title |
| Cardinal HealthCAH | U.S. | Barclays | Target Up | — | Overweight | US$275.00 | US$320.00 | ReportDetailsCardinal Health (CAH) — Barclays raised its price target from $275.00 to $320.00, maintaining an Overweight rating. Report title |
| CaterpillarCAT | U.S. | DA Davidson | Maintains | — | — | — | US$685.00 | ReportDetailsCaterpillar (CAT) — DA Davidson reiterated its price target with a price target of $685.00. Report title |
| CelsiusCELH | U.S. | Wolfe Research | Initiates | — | Outperform | — | US$39.00 | ReportDetailsCelsius (CELH) — Wolfe Research initiated coverage with a Outperform rating and a price target of $39.00. Report title |
| CencoraCOR | U.S. | Barclays | Target Up | — | Overweight | US$350.00 | US$415.00 | ReportDetailsCencora (COR) — Barclays raised its price target from $350.00 to $415.00, maintaining an Overweight rating. Report title |
| CevaCEVA | U.S. | Rosenblatt Securities | Maintains | — | Buy | — | US$49.00 | ReportDetailsCeva (CEVA) — Rosenblatt Securities reiterated its Buy rating with a price target of $49.00. Report title |
| CG OncologyCGON | U.S. | Morgan Stanley | Target Up | — | Overweight | US$102.00 | US$117.00 | ReportDetailsCG Oncology (CGON) — Morgan Stanley raised its price target from $102.00 to $117.00, maintaining an Overweight rating. Report title |
| Charles SchwabSCHW | U.S. | Raymond James | Upgrade | Outperform | Strong Buy | — | US$135.00 | ReportDetailsCharles Schwab (SCHW) — Raymond James upgraded the stock from Outperform to Strong Buy, with a price target of $135. Report title |
| Charles SchwabSCHW | U.S. | Raymond James Financial | Upgrade | Outperform | Strong-Buy | — | US$135.00 | ReportDetailsCharles Schwab (SCHW) — Raymond James Financial upgraded the stock from Outperform to Strong-Buy, with a price target of $135.00. Report title |
| Chemtrade Logistics Income FundCHE.UN:CA | Canada | Scotiabank | Maintains | — | Sector Perform | — | C$19.00 | ReportDetailsChemtrade Logistics Income Fund (CHE.UN:CA) — Scotiabank maintained a Sector Perform rating with a price target of C$19.00. Report title |
| Chime FinancialCHYM | U.S. | B. Riley Financial | Target Up | — | Buy | US$45.00 | US$55.00 | ReportDetailsChime Financial (CHYM) — B. Riley Financial reiterated its Buy rating with its price target from $45.00 to $55.00. Report title |
| Chord EnergyCHRD | U.S. | Morgan Stanley | Target Up | — | Overweight | US$178.00 | US$183.00 | ReportDetailsChord Energy (CHRD) — Morgan Stanley raised its price target from $178.00 to $183.00, maintaining an Overweight rating. Report title |
| Chord EnergyCHRD | U.S. | Truist Financial | Maintains | — | — | — | US$197.00 | ReportDetailsChord Energy (CHRD) — Truist Financial reiterated its price target with a price target of $197.00. Report title |
| Church & DwightCHD | U.S. | Bank of America | Target Up | — | Buy | US$115.00 | US$125.00 | ReportDetailsChurch & Dwight (CHD) — Bank of America raised its price target from $115.00 to $125.00, maintaining a Buy rating. Report title |
| Cleveland-CliffsCLF | U.S. | Wells Fargo & Company | Target Up | — | Overweight | US$17.00 | US$18.00 | ReportDetailsCleveland-Cliffs (CLF) — Wells Fargo & Company raised its price target from $17.00 to $18.00, maintaining an Overweight rating. Report title |
| Climb BioCLYM | U.S. | Royal Bank Of Canada | Maintains | — | Outperform | — | US$23.00 | ReportDetailsClimb Bio (CLYM) — Royal Bank Of Canada reiterated its Outperform rating with a price target of $23.00. Report title |
| CNX ResourcesCNX | U.S. | Morgan Stanley | Upgrade | Underweight | Equal Weight | US$34.00 | US$36.00 | ReportDetailsCNX Resources (CNX) — Morgan Stanley upgraded the stock from Underweight to Equal Weight and changed its price target from $34.00 to $36.00. Report title |
| Coca-ColaKO | U.S. | Wolfe Research | Initiates | — | Outperform | — | — | ReportDetailsCoca-Cola (KO) — Wolfe Research initiated coverage with a Outperform rating. Report title |
| Commercial MetalsCMC | U.S. | Wells Fargo & Company | Target Down | — | Equal Weight | US$70.00 | US$63.00 | ReportDetailsCommercial Metals (CMC) — Wells Fargo & Company lowered its price target from $70.00 to $63.00, maintaining an Equal Weight rating. Report title |
| Comstock ResourcesCRK | U.S. | Barclays | Downgrade | — | Underweight | — | — | ReportDetailsComstock Resources (CRK) — Barclays downgraded the stock to Underweight. Report title |
| Comstock ResourcesCRK | U.S. | Morgan Stanley | Downgrade | Equal Weight | Underweight | — | US$13.00 | ReportDetailsComstock Resources (CRK) — Morgan Stanley downgraded the stock from Equal Weight to Underweight, with a price target of $13.00. Report title |
| ConocoPhillipsCOP | U.S. | Morgan Stanley | Target Up | — | Overweight | US$159.00 | US$160.00 | ReportDetailsConocoPhillips (COP) — Morgan Stanley raised its price target from $159.00 to $160.00, maintaining an Overweight rating. Report title |
| CredicorpBAP | U.S. | UBS Group | Target Down | — | Buy | US$473.00 | US$458.00 | ReportDetailsCredicorp (BAP) — UBS Group lowered its price target from $473.00 to $458.00, maintaining a Buy rating. Report title |
| Crombie REITCRR.UN:CA | Canada | CIBC | Maintains | — | Outperform | — | C$18.00 | ReportDetailsCrombie REIT (CRR.UN:CA) — CIBC maintained an Outperform rating with a price target of C$18.00. Report title |
| Crombie REITCRR.UN:CA | Canada | TD Securities | Resumes | — | Buy | — | C$18.00 | ReportDetailsCrombie REIT (CRR.UN:CA) — TD Securities resumed coverage with a Buy rating and a price target of C$18.00. Report title |
| Cue BiopharmaCUE | U.S. | B. Riley Financial | Maintains | — | Buy | — | — | ReportDetailsCue Biopharma (CUE) — B. Riley Financial reiterated its Buy rating. Report title |
| Deere & CompanyDE | U.S. | Oppenheimer | Maintains | — | Outperform | — | — | ReportDetailsDeere & Company (DE) — Oppenheimer reiterated its Outperform rating. Report title |
| Devon EnergyDVN | U.S. | Morgan Stanley | Target Up | — | Overweight | US$64.00 | US$65.00 | ReportDetailsDevon Energy (DVN) — Morgan Stanley raised its price target from $64.00 to $65.00, maintaining an Overweight rating. Report title |
| Diamondback EnergyFANG | U.S. | Royal Bank Of Canada | Maintains | — | Outperform | — | US$240.00 | ReportDetailsDiamondback Energy (FANG) — Royal Bank Of Canada reiterated its Outperform rating with a price target of $240.00. Report title |
| Disc MedicineIRON | U.S. | Morgan Stanley | Target Up | — | Overweight | US$92.00 | US$104.00 | ReportDetailsDisc Medicine (IRON) — Morgan Stanley raised its price target from $92.00 to $104.00, maintaining an Overweight rating. Report title |
| DLocalDLO | U.S. | Truist Financial | Target Down | — | Buy | US$17.00 | US$16.00 | ReportDetailsDLocal (DLO) — Truist Financial lowered its price target from $17.00 to $16.00, maintaining a Buy rating. Report title |
| DocusignDOCU | U.S. | BTIG Research | Target Up | — | Buy | US$75.00 | US$90.00 | ReportDetailsDocusign (DOCU) — BTIG Research raised its price target from $75.00 to $90.00, maintaining a Buy rating. Report title |
| Dollarama Inc.DOL:CA | Canada | TD Securities | Target Up | — | Buy | C$217.00 | C$250.00 | ReportDetailsDollarama Inc. (DOL:CA) — TD Securities raised its price target from C$217.00 to C$250.00, maintaining a Buy rating and identifying Dollarama as one of its preferred investment ideas for 2027. Report title |
| Duos Technologies GroupDUOT | U.S. | Chardan Capital | Target Down | — | Neutral | US$9.50 | US$5.50 | ReportDetailsDuos Technologies Group (DUOT) — Chardan Capital lowered its price target from $9.50 to $5.50, maintaining a Neutral rating. Report title |
| Dutch BrosBROS | U.S. | Guggenheim | Target Down | — | Buy | US$76.00 | US$62.00 | ReportDetailsDutch Bros (BROS) — Guggenheim lowered its price target from $76.00 to $62.00, maintaining a Buy rating. Report title |
| EatonETN | U.S. | Erste Group Bank | Downgrade | Buy | Hold | — | — | ReportDetailsEaton (ETN) — Erste Group Bank downgraded the stock from Buy to Hold. Report title |
| EcolabECL | U.S. | Oppenheimer | Target Up | — | Outperform | US$320.00 | US$331.00 | ReportDetailsEcolab (ECL) — Oppenheimer raised its price target from $320.00 to $331.00, maintaining an Outperform rating. Report title |
| EcolabECL | U.S. | Robert W. Baird | Target Up | — | Outperform | US$317.00 | US$324.00 | ReportDetailsEcolab (ECL) — Robert W. Baird raised its price target from $317.00 to $324.00, maintaining an Outperform rating. Report title |
| EcolabECL | U.S. | Stifel Nicolaus | Target Up | — | Buy | US$337.00 | US$356.00 | ReportDetailsEcolab (ECL) — Stifel Nicolaus raised its price target from $337.00 to $356.00, maintaining a Buy rating. Report title |
| Eikon TherapeuticsEIKN | U.S. | Morgan Stanley | Target Down | — | Overweight | — | US$30.00 | ReportDetailsEikon Therapeutics (EIKN) — Morgan Stanley lowered its price target to $30.00, maintaining an Overweight rating. Report title |
| Elbit SystemsESLT | U.S. | JPMorgan Chase & Co. | Target Up | — | Neutral | US$885.00 | US$900.00 | ReportDetailsElbit Systems (ESLT) — JPMorgan Chase & Co. raised its price target from $885.00 to $900.00, maintaining a Neutral rating. Report title |
| Elevance HealthELV | U.S. | Argus | Upgrade | Hold | Buy | — | US$510.00 | ReportDetailsElevance Health (ELV) — Argus upgraded the stock from Hold to Buy, with a price target of $510.00. Report title |
| EnergizerENR | U.S. | JPMorgan Chase & Co. | Target Up | — | Neutral | US$22.00 | US$25.00 | ReportDetailsEnergizer (ENR) — JPMorgan Chase & Co. raised its price target from $22.00 to $25.00, maintaining a Neutral rating. Report title |
| EnergizerENR | U.S. | Morgan Stanley | Target Up | — | Equal Weight | US$21.00 | US$27.00 | ReportDetailsEnergizer (ENR) — Morgan Stanley raised its price target from $21.00 to $27.00, maintaining an Equal Weight rating. Report title |
| EnergizerENR | U.S. | UBS Group | Target Up | — | Neutral | US$22.00 | US$28.00 | ReportDetailsEnergizer (ENR) — UBS Group raised its price target from $22.00 to $28.00, maintaining a Neutral rating. Report title |
| EnovixENVX | U.S. | Bank of America | Downgrade | Neutral | Underperform | US$5.00 | US$1.00 | ReportDetailsEnovix (ENVX) — Bank of America downgraded the stock from Neutral to Underperform and changed its price target from $5.00 to $1.00. Report title |
| Entrada TherapeuticsTRDA | U.S. | Guggenheim | Target Down | — | Buy | US$17.00 | US$13.00 | ReportDetailsEntrada Therapeutics (TRDA) — Guggenheim lowered its price target from $17.00 to $13.00, maintaining a Buy rating. Report title |
| EOG ResourcesEOG | U.S. | Morgan Stanley | Target Up | — | Equal Weight | US$163.00 | US$167.00 | ReportDetailsEOG Resources (EOG) — Morgan Stanley raised its price target from $163.00 to $167.00, maintaining an Equal Weight rating. Report title |
| EQT CorporationEQT | U.S. | Morgan Stanley | Target Down | — | Overweight | US$67.00 | US$66.00 | ReportDetailsEQT Corporation (EQT) — Morgan Stanley lowered its price target from $67.00 to $66.00, maintaining an Overweight rating. Report title |
| Expand EnergyEXE | U.S. | Morgan Stanley | Target Down | — | Overweight | US$123.00 | US$120.00 | ReportDetailsExpand Energy (EXE) — Morgan Stanley lowered its price target from $123.00 to $120.00, maintaining an Overweight rating. Report title |
| ExxonMobilXOM | U.S. | Erste Group Bank | Upgrade | Hold | Buy | — | — | ReportDetailsExxonMobil (XOM) — Erste Group Bank upgraded the stock from Hold to Buy. Report title |
| FergusonFERG | U.S. | Bank of America | Target Up | — | Buy | US$315.00 | US$320.00 | ReportDetailsFerguson (FERG) — Bank of America raised its price target from $315.00 to $320.00, maintaining a Buy rating. Report title |
| Franco-Nevada CorporationFNV:CA | Canada | CIBC | Maintains | — | Outperform | — | C$480.00 | ReportDetailsFranco-Nevada Corporation (FNV:CA) — CIBC maintained an Outperform rating with a price target of C$480.00. Report title |
| Freeport-McMoRanFCX | U.S. | Erste Group Bank | Downgrade | Buy | Hold | — | — | ReportDetailsFreeport-McMoRan (FCX) — Erste Group Bank downgraded the stock from Buy to Hold. Report title |
| fuboTVFUBO | U.S. | Barrington Research | Target Down | — | Outperform | US$16.00 | US$12.00 | ReportDetailsfuboTV (FUBO) — Barrington Research lowered its price target from $16.00 to $12.00, maintaining an Outperform rating. Report title |
| fuboTVFUBO | U.S. | BTIG Research | Maintains | — | Neutral | — | — | ReportDetailsfuboTV (FUBO) — BTIG Research reiterated its Neutral rating. Report title |
| FutuFUTU | U.S. | JPMorgan Chase & Co. | Target Down | — | Neutral | US$122.00 | US$103.00 | ReportDetailsFutu (FUTU) — JPMorgan Chase & Co. lowered its price target from $122.00 to $103.00, maintaining a Neutral rating. Report title |
| GE HealthCare TechnologiesGEHC | U.S. | BTIG Research | Target Up | — | Buy | US$83.00 | US$91.00 | ReportDetailsGE HealthCare Technologies (GEHC) — BTIG Research raised its price target from $83.00 to $91.00, maintaining a Buy rating. Report title |
| GE VernovaGEV | U.S. | Erste Group Bank | Downgrade | Buy | Hold | — | — | ReportDetailsGE Vernova (GEV) — Erste Group Bank downgraded the stock from Buy to Hold. Report title |
| GeneDxWGS | U.S. | BTIG Research | Maintains | — | Buy | — | US$85.00 | ReportDetailsGeneDx (WGS) — BTIG Research reiterated its Buy rating with a price target of $85.00. Report title |
| General Fusion GroupGFUZ | U.S. | Wedbush | Maintains | — | Neutral | — | US$7.00 | ReportDetailsGeneral Fusion Group (GFUZ) — Wedbush reiterated its Neutral rating with a price target of $7.00. Report title |
| Generate BiomedicinesGENB | U.S. | Morgan Stanley | Target Down | — | Overweight | US$22.00 | US$21.00 | ReportDetailsGenerate Biomedicines (GENB) — Morgan Stanley lowered its price target from $22.00 to $21.00, maintaining an Overweight rating. Report title |
| Geo GroupGEO | U.S. | JonesTrading | Maintains | — | Buy | — | US$42.75 | ReportDetailsGeo Group (GEO) — JonesTrading reiterated its Buy rating with a price target of $42.75. Report title |
| GH ResearchGHRS | U.S. | Guggenheim | Target Up | — | Buy | US$40.00 | US$46.00 | ReportDetailsGH Research (GHRS) — Guggenheim raised its price target from $40.00 to $46.00, maintaining a Buy rating. Report title |
| Granite Point Mortgage TrustGPMT | U.S. | UBS Group | Target Down | — | Neutral | — | US$3.00 | ReportDetailsGranite Point Mortgage Trust (GPMT) — UBS Group lowered its price target to $3.00, maintaining a Neutral rating. Report title |
| Gray MediaGTN | U.S. | Guggenheim | Target Up | — | Buy | US$7.00 | US$8.00 | ReportDetailsGray Media (GTN) — Guggenheim raised its price target from $7.00 to $8.00, maintaining a Buy rating. Report title |
| Greenwich LifeSciencesGLSI | U.S. | HC Wainwright | Target Up | — | Buy | US$69.00 | US$70.00 | ReportDetailsGreenwich LifeSciences (GLSI) — HC Wainwright raised its price target from $69.00 to $70.00, maintaining a Buy rating. Report title |
| Groupe Dynamite Inc.GRGD:CA | Canada | Scotiabank | Maintains | — | Sector Outperform | — | C$75.00 | ReportDetailsGroupe Dynamite Inc. (GRGD:CA) — Scotiabank maintained a Sector Outperform rating with a price target of C$75.00. Report title |
| Guardant HealthGH | U.S. | TD Cowen | Maintains | — | Buy | — | — | ReportDetailsGuardant Health (GH) — TD Cowen reiterated its Buy rating. Report title |
| HA Sustainable Infrastructure CapitalHASI | U.S. | Jefferies Financial Group | Maintains | — | Buy | — | US$46.00 | ReportDetailsHA Sustainable Infrastructure Capital (HASI) — Jefferies Financial Group reiterated its Buy rating with a price target of $46.00. Report title |
| HCA HealthcareHCA | U.S. | JPMorgan Chase & Co. | Target Up | — | Neutral | US$425.00 | US$475.00 | ReportDetailsHCA Healthcare (HCA) — JPMorgan Chase & Co. raised its price target from $425.00 to $475.00, maintaining a Neutral rating. Report title |
| HersheyHSY | U.S. | TD Cowen | Maintains | — | Hold | — | US$173.00 | ReportDetailsHershey (HSY) — TD Cowen reiterated its Hold rating with a price target of $173.00. Report title |
| Home DepotHD | U.S. | DA Davidson | Target Up | — | Buy | US$377.00 | US$390.00 | ReportDetailsHome Depot (HD) — DA Davidson raised its price target from $377.00 to $390.00, maintaining a Buy rating. Report title |
| Home DepotHD | U.S. | JPMorgan Chase & Co. | Maintains | — | — | — | US$390.00 | ReportDetailsHome Depot (HD) — JPMorgan Chase & Co. reiterated its price target with a price target of $390.00. Report title |
| Home DepotHD | U.S. | Mizuho | Target Down | — | Outperform | US$390.00 | US$385.00 | ReportDetailsHome Depot (HD) — Mizuho lowered its price target from $390.00 to $385.00, maintaining an Outperform rating. Report title |
| Home DepotHD | U.S. | Royal Bank Of Canada | Target Down | — | Sector Perform | US$342.00 | US$334.00 | ReportDetailsHome Depot (HD) — Royal Bank Of Canada lowered its price target from $342.00 to $334.00, maintaining a Sector Perform rating. Report title |
| Home DepotHD | U.S. | Sanford C. Bernstein | Target Up | — | Market Perform | US$357.00 | US$360.00 | ReportDetailsHome Depot (HD) — Sanford C. Bernstein raised its price target from $357.00 to $360.00, maintaining a Market Perform rating. Report title |
| Home DepotHD | U.S. | Truist Financial | Target Up | — | Buy | US$373.00 | US$376.00 | ReportDetailsHome Depot (HD) — Truist Financial raised its price target from $373.00 to $376.00, maintaining a Buy rating. Report title |
| Home DepotHD | U.S. | UBS Group | Target Down | — | Buy | US$420.00 | US$417.00 | ReportDetailsHome Depot (HD) — UBS Group lowered its price target from $420.00 to $417.00, maintaining a Buy rating. Report title |
| Hornbeck Offshore ServicesHOS | U.S. | Pickering Energy Partners | Upgrade | Neutral | Outperform | — | — | ReportDetailsHornbeck Offshore Services (HOS) — Pickering Energy Partners upgraded the stock from Neutral to Outperform. Report title |
| HyperfineHYPR | U.S. | B. Riley Financial | Target Down | — | Buy | US$1.60 | US$1.40 | ReportDetailsHyperfine (HYPR) — B. Riley Financial reiterated its Buy rating with its price target from $1.60 to $1.40. Report title |
| Immix BiopharmaIMMX | U.S. | Mizuho | Target Down | — | Outperform | US$23.00 | US$22.00 | ReportDetailsImmix Biopharma (IMMX) — Mizuho lowered its price target from $23.00 to $22.00, maintaining an Outperform rating. Report title |
| Immix BiopharmaIMMX | U.S. | Morgan Stanley | Target Up | — | Overweight | US$20.00 | US$21.00 | ReportDetailsImmix Biopharma (IMMX) — Morgan Stanley raised its price target from $20.00 to $21.00, maintaining an Overweight rating. Report title |
| ImmunicIMUX | U.S. | HC Wainwright | Maintains | — | Buy | — | — | ReportDetailsImmunic (IMUX) — HC Wainwright reiterated its Buy rating. Report title |
| Imperial Oil Ltd.IMO:CA | Canada | BMO | Target Up | — | Underperform | C$133.00 | C$138.00 | ReportDetailsImperial Oil Ltd. (IMO:CA) — BMO raised its price target from C$133.00 to C$138.00, maintaining an Underperform rating. Report title |
| InnovivaINVA | U.S. | Piper Sandler | Initiates | — | Overweight | — | US$29.00 | ReportDetailsInnoviva (INVA) — Piper Sandler initiated coverage with a Overweight rating and a price target of $29.00. Report title |
| InsuletPODD | U.S. | Stifel Nicolaus | Downgrade | Buy | Hold | US$180.00 | US$165.00 | ReportDetailsInsulet (PODD) — Stifel Nicolaus downgraded the stock from Buy to Hold and changed its price target from $180.00 to $165.00. Report title |
| Intuitive SurgicalISRG | U.S. | BTIG Research | Target Up | — | Buy | US$454.00 | US$513.00 | ReportDetailsIntuitive Surgical (ISRG) — BTIG Research raised its price target from $454.00 to $513.00, maintaining a Buy rating. Report title |
| Ionis PharmaceuticalsIONS | U.S. | Guggenheim | Target Down | — | Buy | US$80.00 | US$65.00 | ReportDetailsIonis Pharmaceuticals (IONS) — Guggenheim lowered its price target from $80.00 to $65.00, maintaining a Buy rating. Report title |
| ITT Inc.ITT | U.S. | TD Cowen | Target Up | — | Buy | US$250.00 | US$260.00 | ReportDetailsITT Inc. (ITT) — TD Cowen raised its price target from $250.00 to $260.00, maintaining a Buy rating. Report title |
| J. M. SmuckerSJM | U.S. | UBS Group | Target Up | — | Buy | US$149.00 | US$153.00 | ReportDetailsJ. M. Smucker (SJM) — UBS Group raised its price target from $149.00 to $153.00, maintaining a Buy rating. Report title |
| Jamieson Wellness Inc.JWEL:CA | Canada | TD Securities | Maintains | — | Sell | — | C$45.75 | ReportDetailsJamieson Wellness Inc. (JWEL:CA) — TD Securities maintained a Sell rating with a price target of C$45.75. Report title |
| JD.comJD | U.S. | Barclays | Target Down | — | Overweight | US$38.00 | US$33.00 | ReportDetailsJD.com (JD) — Barclays lowered its price target from $38.00 to $33.00, maintaining an Overweight rating. Report title |
| JD.comJD | U.S. | Mizuho | Target Down | — | Outperform | US$37.00 | US$34.00 | ReportDetailsJD.com (JD) — Mizuho lowered its price target from $37.00 to $34.00, maintaining an Outperform rating. Report title |
| JD.comJD | U.S. | Sanford C. Bernstein | Target Down | — | Outperform | US$40.00 | US$38.00 | ReportDetailsJD.com (JD) — Sanford C. Bernstein lowered its price target from $40.00 to $38.00, maintaining an Outperform rating. Report title |
| JD.comJD | U.S. | StoneX | Maintains | — | — | — | US$42.00 | ReportDetailsJD.com (JD) — StoneX reiterated its price target with a price target of $42.00. Report title |
| Kelt Exploration Ltd.KEL:CA | Canada | Scotiabank | Target Up | — | Sector Outperform | C$13.50 | C$14.00 | ReportDetailsKelt Exploration Ltd. (KEL:CA) — Scotiabank raised its price target from C$13.50 to C$14.00, maintaining a Sector Outperform rating. Report title |
| Keurig Dr PepperKDP | U.S. | Wolfe Research | Initiates | — | Outperform | — | US$42.00 | ReportDetailsKeurig Dr Pepper (KDP) — Wolfe Research initiated coverage with a Outperform rating and a price target of $42.00. Report title |
| Klarna GroupKLAR | U.S. | Bank of America | Target Up | — | Buy | US$19.00 | US$20.00 | ReportDetailsKlarna Group (KLAR) — Bank of America raised its price target from $19.00 to $20.00, maintaining a Buy rating. Report title |
| Klarna GroupKLAR | U.S. | BMO Capital Markets | Target Down | — | Market Perform | US$14.00 | US$13.00 | ReportDetailsKlarna Group (KLAR) — BMO Capital Markets lowered its price target from $14.00 to $13.00, maintaining a Market Perform rating. Report title |
| Klarna GroupKLAR | U.S. | JPMorgan Chase & Co. | Target Down | — | Neutral | US$18.00 | US$17.00 | ReportDetailsKlarna Group (KLAR) — JPMorgan Chase & Co. lowered its price target from $18.00 to $17.00, maintaining a Neutral rating. Report title |
| Klarna GroupKLAR | U.S. | Morgan Stanley | Target Down | — | Equal Weight | US$17.00 | US$14.00 | ReportDetailsKlarna Group (KLAR) — Morgan Stanley lowered its price target from $17.00 to $14.00, maintaining an Equal Weight rating. Report title |
| Lantern PharmaLTRN | U.S. | Rodman & Renshaw | Downgrade | Buy | Neutral | — | — | ReportDetailsLantern Pharma (LTRN) — Rodman & Renshaw downgraded the stock from Buy to Neutral. Report title |
| Liberty GlobalLBTYA | U.S. | Citigroup | Resumes | — | Neutral | — | US$11.00 | ReportDetailsLiberty Global (LBTYA) — Citigroup resumed coverage with a Neutral rating and a price target of $11.00. Report title |
| LifeMDLFMD | U.S. | HC Wainwright | Target Down | — | Buy | US$9.00 | US$6.00 | ReportDetailsLifeMD (LFMD) — HC Wainwright lowered its price target from $9.00 to $6.00, maintaining a Buy rating. Report title |
| Liftoff MobileLFTO | U.S. | UBS Group | Target Up | — | Buy | US$25.00 | US$35.00 | ReportDetailsLiftoff Mobile (LFTO) — UBS Group raised its price target from $25.00 to $35.00, maintaining a Buy rating. Report title |
| Lodestar Metals Corp.LSTR:CA | Canada | Fundamental Research | Maintains | — | Buy | — | C$0.33 | ReportDetailsLodestar Metals Corp. (LSTR:CA) — Fundamental Research maintained a Buy rating with a price target of C$0.33. Report title |
| Lowe's CompaniesLOW | U.S. | TD Cowen | Maintains | — | Hold | — | US$235.00 | ReportDetailsLowe's Companies (LOW) — TD Cowen reiterated its Hold rating with a price target of $235.00. Report title |
| Lowe's CompaniesLOW | U.S. | Truist Financial | Maintains | — | — | — | US$254.00 | ReportDetailsLowe's Companies (LOW) — Truist Financial reiterated its price target with a price target of $254.00. Report title |
| Lumexa ImagingLMRI | U.S. | Wells Fargo & Company | Target Up | — | Overweight | US$19.00 | US$21.00 | ReportDetailsLumexa Imaging (LMRI) — Wells Fargo & Company raised its price target from $19.00 to $21.00, maintaining an Overweight rating. Report title |
| LuxExperience B.V.LUXE | U.S. | B. Riley Financial | Target Up | — | Buy | US$13.00 | US$14.00 | ReportDetailsLuxExperience B.V. (LUXE) — B. Riley Financial reiterated its Buy rating with its price target from $13.00 to $14.00. Report title |
| LuxExperience B.V.LUXE | U.S. | TD Cowen | Target Up | — | Buy | US$12.00 | US$13.50 | ReportDetailsLuxExperience B.V. (LUXE) — TD Cowen raised its price target from $12.00 to $13.50, maintaining a Buy rating. Report title |
| Manhattan AssociatesMANH | U.S. | JPMorgan Chase & Co. | Initiates | — | Overweight | — | US$308.00 | ReportDetailsManhattan Associates (MANH) — JPMorgan Chase & Co. initiated coverage with a Overweight rating and a price target of $308.00. Report title |
| MARA HoldingsMARA | U.S. | BTIG Research | Maintains | — | Buy | — | US$27.00 | ReportDetailsMARA Holdings (MARA) — BTIG Research reiterated its Buy rating with a price target of $27.00. Report title |
| Matador ResourcesMTDR | U.S. | Morgan Stanley | Target Up | — | Equal Weight | US$69.00 | US$70.00 | ReportDetailsMatador Resources (MTDR) — Morgan Stanley raised its price target from $69.00 to $70.00, maintaining an Equal Weight rating. Report title |
| McDonald'sMCD | U.S. | KeyCorp | Maintains | — | Overweight | — | — | ReportDetailsMcDonald's (MCD) — KeyCorp reiterated its Overweight rating. Report title |
| McKessonMCK | U.S. | Barclays | Target Up | — | Overweight | US$1,000.00 | US$1,235.00 | ReportDetailsMcKesson (MCK) — Barclays raised its price target from $1,000.00 to $1,235.00, maintaining an Overweight rating. Report title |
| MDU Resources GroupMDU | U.S. | TD Cowen | Maintains | — | Hold | — | US$22.00 | ReportDetailsMDU Resources Group (MDU) — TD Cowen reiterated its Hold rating with a price target of $22.00. Report title |
| Metro Inc.MRU:CA | Canada | CIBC | Maintains | — | Outperform | — | C$112.00 | ReportDetailsMetro Inc. (MRU:CA) — CIBC maintained an Outperform rating with a price target of C$112.00. Report title |
| Metro Inc.MRU:CA | Canada | TD Securities | Maintains | — | Buy | — | C$108.00 | ReportDetailsMetro Inc. (MRU:CA) — TD Securities maintained a Buy rating with a price target of C$108.00. Report title |
| Micron TechnologyMU | U.S. | Royal Bank Of Canada | Maintains | — | Outperform | — | US$1,500.00 | ReportDetailsMicron Technology (MU) — Royal Bank Of Canada reiterated its Outperform rating with a price target of $1,500.00. Report title |
| MicrosoftMSFT | U.S. | JPMorgan Chase & Co. | Maintains | — | — | — | US$625.00 | ReportDetailsMicrosoft (MSFT) — JPMorgan Chase & Co. reiterated its price target with a price target of $625.00. Report title |
| MicrosoftMSFT | U.S. | Mizuho | Maintains | — | — | — | US$625.00 | ReportDetailsMicrosoft (MSFT) — Mizuho reiterated its price target with a price target of $625.00. Report title |
| MicrosoftMSFT | U.S. | Oppenheimer | Maintains | — | Outperform | — | — | ReportDetailsMicrosoft (MSFT) — Oppenheimer reiterated its Outperform rating. Report title |
| MicrosoftMSFT | U.S. | Piper Sandler | Maintains | — | Overweight | — | — | ReportDetailsMicrosoft (MSFT) — Piper Sandler reiterated its Overweight rating. Report title |
| MicrosoftMSFT | U.S. | TD Cowen | Maintains | — | Buy | — | US$650.00 | ReportDetailsMicrosoft (MSFT) — TD Cowen reiterated its Buy rating with a price target of $650.00. Report title |
| MicrosoftMSFT | U.S. | UBS Group | Maintains | — | Overweight | — | — | ReportDetailsMicrosoft (MSFT) — UBS Group reiterated its Overweight rating. Report title |
| MiddlebyMIDD | U.S. | Oppenheimer | Maintains | — | Outperform | — | — | ReportDetailsMiddleby (MIDD) — Oppenheimer reiterated its Outperform rating. Report title |
| Midera Food ProcessingMFP | U.S. | Robert W. Baird | Target Up | — | Neutral | US$40.00 | US$43.00 | ReportDetailsMidera Food Processing (MFP) — Robert W. Baird raised its price target from $40.00 to $43.00, maintaining a Neutral rating. Report title |
| Millicom International CellularTIGO | U.S. | JPMorgan Chase & Co. | Upgrade | Neutral | Overweight | — | US$105.00 | ReportDetailsMillicom International Cellular (TIGO) — JPMorgan Chase & Co. upgraded the stock from Neutral to Overweight, with a price target of $105.00. Report title |
| Molson Coors BeverageTAP | U.S. | Wolfe Research | Initiates | — | — | — | — | ReportDetailsMolson Coors Beverage (TAP) — Wolfe Research initiated coverage with a Peer Perform rating. Report title |
| Monster BeverageMNST | U.S. | Wolfe Research | Initiates | — | Outperform | — | — | ReportDetailsMonster Beverage (MNST) — Wolfe Research initiated coverage with a Outperform rating. Report title |
| MP MaterialsMP | U.S. | Needham | Resumes | — | Buy | — | US$48.00 | ReportDetailsMP Materials (MP) — Needham resumed coverage with a Buy rating and a price target of $48. Report title |
| MP MaterialsMP | U.S. | Needham & Company LLC | Initiates | — | Buy | — | US$48.00 | ReportDetailsMP Materials (MP) — Needham & Company LLC initiated coverage with a Buy rating and a price target of $48.00. Report title |
| Murphy OilMUR | U.S. | Morgan Stanley | Target Up | — | Underweight | US$37.00 | US$39.00 | ReportDetailsMurphy Oil (MUR) — Morgan Stanley raised its price target from $37.00 to $39.00, maintaining an Underweight rating. Report title |
| New York TimesNYT | U.S. | Citigroup | Downgrade | Buy | Neutral | US$85.00 | US$76.00 | ReportDetailsNew York Times (NYT) — Citigroup downgraded the stock from Buy to Neutral and changed its price target from $85.00 to $76.00. Report title |
| NIKENKE | U.S. | Barclays | Target Down | — | Overweight | US$45.00 | US$42.00 | ReportDetailsNIKE (NKE) — Barclays lowered its price target from $45.00 to $42.00, maintaining an Overweight rating. Report title |
| NIKENKE | U.S. | BMO Capital Markets | Maintains | — | Underperform | — | — | ReportDetailsNIKE (NKE) — BMO Capital Markets reiterated its Underperform rating. Report title |
| NIKENKE | U.S. | BTIG Research | Maintains | — | Buy | — | — | ReportDetailsNIKE (NKE) — BTIG Research reiterated its Buy rating. Report title |
| NIKENKE | U.S. | JPMorgan Chase & Co. | Maintains | — | — | — | US$38.00 | ReportDetailsNIKE (NKE) — JPMorgan Chase & Co. reiterated its price target with a price target of $38.00. Report title |
| NIKENKE | U.S. | Needham & Company LLC | Maintains | — | Hold | — | — | ReportDetailsNIKE (NKE) — Needham & Company LLC reiterated its Hold rating. Report title |
| NucorNUE | U.S. | Wells Fargo & Company | Target Up | — | Overweight | US$305.00 | US$308.00 | ReportDetailsNucor (NUE) — Wells Fargo & Company raised its price target from $305.00 to $308.00, maintaining an Overweight rating. Report title |
| NVIDIANVDA | U.S. | Argus | Maintains | — | Buy | — | US$220.00 | ReportDetailsNVIDIA (NVDA) — Argus reiterated its Buy rating with a price target of $220.00. Report title |
| NVIDIANVDA | U.S. | BMO Capital Markets | Maintains | — | Outperform | — | — | ReportDetailsNVIDIA (NVDA) — BMO Capital Markets reiterated its Outperform rating. Report title |
| NVIDIANVDA | U.S. | Citigroup | Maintains | — | — | — | US$225.00 | ReportDetailsNVIDIA (NVDA) — Citigroup reiterated its price target with a price target of $225.00. Report title |
| NVIDIANVDA | U.S. | DA Davidson | Maintains | — | Buy | — | US$200.00 | ReportDetailsNVIDIA (NVDA) — DA Davidson reiterated its Buy rating with a price target of $200.00. Report title |
| NVIDIANVDA | U.S. | HSBC | Maintains | — | — | — | US$170.00 | ReportDetailsNVIDIA (NVDA) — HSBC reiterated its price target with a price target of $170.00. Report title |
| NVIDIANVDA | U.S. | Jefferies Financial Group | Target Down | — | Buy | US$300.00 | US$250.00 | ReportDetailsNVIDIA (NVDA) — Jefferies Financial Group reiterated its Buy rating with its price target from $300.00 to $250.00. Report title |
| NVIDIANVDA | U.S. | JPMorgan Chase & Co. | Target Up | — | Overweight | US$215.00 | US$230.00 | ReportDetailsNVIDIA (NVDA) — JPMorgan Chase & Co. reiterated its Overweight rating with its price target from $215.00 to $230.00. Report title |
| NVIDIANVDA | U.S. | KeyCorp | Maintains | — | — | — | — | ReportDetailsNVIDIA (NVDA) — KeyCorp reiterated its Sector Weight rating. Report title |
| NVIDIANVDA | U.S. | Melius Research | Maintains | — | — | — | US$185.00 | ReportDetailsNVIDIA (NVDA) — Melius Research reiterated its price target with a price target of $185.00. Report title |
| NVIDIANVDA | U.S. | Morgan Stanley | Target Down | — | Overweight | US$267.00 | US$260.00 | ReportDetailsNVIDIA (NVDA) — Morgan Stanley lowered its price target from $267.00 to $260.00, maintaining an Overweight rating. Report title |
| NVIDIANVDA | U.S. | Needham & Company LLC | Maintains | — | Buy | — | US$200.00 | ReportDetailsNVIDIA (NVDA) — Needham & Company LLC reiterated its Buy rating with a price target of $200.00. Report title |
| NVIDIANVDA | U.S. | Piper Sandler | Target Down | — | Overweight | US$300.00 | US$230.00 | ReportDetailsNVIDIA (NVDA) — Piper Sandler reiterated its Overweight rating with its price target from $300.00 to $230.00. Report title |
| NVIDIANVDA | U.S. | Royal Bank Of Canada | Maintains | — | Outperform | — | US$230.00 | ReportDetailsNVIDIA (NVDA) — Royal Bank Of Canada reiterated its Outperform rating with a price target of $230.00. Report title |
| NVIDIANVDA | U.S. | Summit Insights | Downgrade | Buy | Hold | — | — | ReportDetailsNVIDIA (NVDA) — Summit Insights downgraded the stock from Buy to Hold. Report title |
| NVIDIANVDA | U.S. | Susquehanna | Maintains | — | Positive | — | — | ReportDetailsNVIDIA (NVDA) — Susquehanna reiterated its Positive rating. Report title |
| NVIDIANVDA | U.S. | Truist Financial | Maintains | — | — | — | US$174.00 | ReportDetailsNVIDIA (NVDA) — Truist Financial reiterated its price target with a price target of $174.00. Report title |
| NVIDIANVDA | U.S. | Wedbush | Target Up | — | Outperform | US$275.00 | US$293.00 | ReportDetailsNVIDIA (NVDA) — Wedbush raised its price target from $275.00 to $293.00, maintaining an Outperform rating. Report title |
| NVIDIANVDA | U.S. | Wells Fargo & Company | Target Down | — | Overweight | US$300.00 | US$250.00 | ReportDetailsNVIDIA (NVDA) — Wells Fargo & Company lowered its price target from $300.00 to $250.00, maintaining an Overweight rating. Report title |
| Oaktree Specialty LendingOCSL | U.S. | Keefe, Bruyette & Woods | Target Down | — | Market Perform | US$13.50 | US$12.50 | ReportDetailsOaktree Specialty Lending (OCSL) — Keefe, Bruyette & Woods lowered its price target from $13.50 to $12.50, maintaining a Market Perform rating. Report title |
| OGE EnergyOGE | U.S. | JPMorgan Chase & Co. | Target Up | — | Overweight | US$53.00 | US$56.00 | ReportDetailsOGE Energy (OGE) — JPMorgan Chase & Co. raised its price target from $53.00 to $56.00, maintaining an Overweight rating. Report title |
| Once Upon A FarmOFRM | U.S. | JPMorgan Chase & Co. | Target Up | — | Overweight | US$13.00 | US$14.00 | ReportDetailsOnce Upon A Farm (OFRM) — JPMorgan Chase & Co. raised its price target from $13.00 to $14.00, maintaining an Overweight rating. Report title |
| OncocyteIMDX | U.S. | Stephens | Maintains | — | Equal Weight | — | US$4.00 | ReportDetailsOncocyte (IMDX) — Stephens reiterated its Equal Weight rating with a price target of $4.00. Report title |
| OneWater MarineONEW | U.S. | KeyCorp | Maintains | — | Overweight | — | — | ReportDetailsOneWater Marine (ONEW) — KeyCorp reiterated its Overweight rating. Report title |
| OperaOPRA | U.S. | B. Riley Financial | Target Down | — | Buy | US$28.00 | US$27.00 | ReportDetailsOpera (OPRA) — B. Riley Financial lowered its price target from $28.00 to $27.00, maintaining a Buy rating. Report title |
| Oric PharmaceuticalsORIC | U.S. | Wells Fargo & Company | Target Down | — | Overweight | US$25.00 | US$23.00 | ReportDetailsOric Pharmaceuticals (ORIC) — Wells Fargo & Company lowered its price target from $25.00 to $23.00, maintaining an Overweight rating. Report title |
| OrthoPediatricsKIDS | U.S. | BTIG Research | Target Up | — | Buy | US$30.00 | US$40.00 | ReportDetailsOrthoPediatrics (KIDS) — BTIG Research raised its price target from $30.00 to $40.00, maintaining a Buy rating. Report title |
| OvintivOVV | U.S. | Morgan Stanley | Target Up | — | Equal Weight | US$71.00 | US$72.00 | ReportDetailsOvintiv (OVV) — Morgan Stanley raised its price target from $71.00 to $72.00, maintaining an Equal Weight rating. Report title |
| PaysafePSFE | U.S. | Susquehanna | Target Down | — | Neutral | US$7.00 | US$3.50 | ReportDetailsPaysafe (PSFE) — Susquehanna lowered its price target from $7.00 to $3.50, maintaining a Neutral rating. Report title |
| PepsiCoPEP | U.S. | Wolfe Research | Initiates | — | — | — | — | ReportDetailsPepsiCo (PEP) — Wolfe Research initiated coverage with a Peer Perform rating. Report title |
| Petroleo Brasileiro S.A. - PetrobrasPBR | U.S. | JPMorgan Chase & Co. | Target Down | — | Overweight | US$24.00 | US$23.50 | ReportDetailsPetroleo Brasileiro S.A. - Petrobras (PBR) — JPMorgan Chase & Co. lowered its price target from $24.00 to $23.50, maintaining an Overweight rating. Report title |
| Phathom PharmaceuticalsPHAT | U.S. | Barclays | Target Down | — | Overweight | US$14.00 | US$10.00 | ReportDetailsPhathom Pharmaceuticals (PHAT) — Barclays lowered its price target from $14.00 to $10.00, maintaining an Overweight rating. Report title |
| Pilgrim's PridePPC | U.S. | UBS Group | Target Up | — | Neutral | US$28.00 | US$31.00 | ReportDetailsPilgrim's Pride (PPC) — UBS Group raised its price target from $28.00 to $31.00, maintaining a Neutral rating. Report title |
| Planet FitnessPLNT | U.S. | UBS Group | Target Up | — | Buy | US$80.00 | US$83.00 | ReportDetailsPlanet Fitness (PLNT) — UBS Group raised its price target from $80.00 to $83.00, maintaining a Buy rating. Report title |
| PMET Resources Inc.PMET:CA | Canada | National Bank | Target Up | — | Outperform | C$7.75 | C$8.50 | ReportDetailsPMET Resources Inc. (PMET:CA) — National Bank raised its price target from C$7.75 to C$8.50, maintaining an Outperform rating. Report title |
| Portland General ElectricPOR | U.S. | JPMorgan Chase & Co. | Target Down | — | Neutral | US$50.00 | US$48.00 | ReportDetailsPortland General Electric (POR) — JPMorgan Chase & Co. lowered its price target from $50.00 to $48.00, maintaining a Neutral rating. Report title |
| Portman Ridge FinanceBCIC | U.S. | Keefe, Bruyette & Woods | Target Down | — | Market Perform | US$7.50 | US$6.50 | ReportDetailsPortman Ridge Finance (BCIC) — Keefe, Bruyette & Woods lowered its price target from $7.50 to $6.50, maintaining a Market Perform rating. Report title |
| Prelude TherapeuticsPRLD | U.S. | HC Wainwright | Maintains | — | Buy | — | US$8.00 | ReportDetailsPrelude Therapeutics (PRLD) — HC Wainwright reiterated its Buy rating with a price target of $8.00. Report title |
| Procter & GamblePG | U.S. | Wells Fargo & Company | Target Up | — | Overweight | US$180.00 | US$188.00 | ReportDetailsProcter & Gamble (PG) — Wells Fargo & Company raised its price target from $180.00 to $188.00, maintaining an Overweight rating. Report title |
| PulmonxLUNG | U.S. | Loop Capital | Maintains | — | — | — | US$7.00 | ReportDetailsPulmonx (LUNG) — Loop Capital reiterated its price target with a price target of $7.00. Report title |
| QualcommQCOM | U.S. | Robert W. Baird | Target Down | — | Outperform | US$320.00 | US$300.00 | ReportDetailsQualcomm (QCOM) — Robert W. Baird lowered its price target from $320.00 to $300.00, maintaining an Outperform rating. Report title |
| Range ResourcesRRC | U.S. | Morgan Stanley | Target Up | — | Equal Weight | US$45.00 | US$50.00 | ReportDetailsRange Resources (RRC) — Morgan Stanley raised its price target from $45.00 to $50.00, maintaining an Equal Weight rating. Report title |
| Recursion PharmaceuticalsRXRX | U.S. | Morgan Stanley | Target Down | — | Equal Weight | US$5.90 | US$5.60 | ReportDetailsRecursion Pharmaceuticals (RXRX) — Morgan Stanley lowered its price target from $5.90 to $5.60, maintaining an Equal Weight rating. Report title |
| Rein TherapeuticsRNTX | U.S. | HC Wainwright | Maintains | — | Buy | — | — | ReportDetailsRein Therapeutics (RNTX) — HC Wainwright reiterated its Buy rating. Report title |
| RelianceRS | U.S. | Wells Fargo & Company | Target Up | — | Equal Weight | US$420.00 | US$452.00 | ReportDetailsReliance (RS) — Wells Fargo & Company raised its price target from $420.00 to $452.00, maintaining an Equal Weight rating. Report title |
| RelxRELX | U.S. | Erste Group Bank | Initiates | — | Buy | — | — | ReportDetailsRelx (RELX) — Erste Group Bank initiated coverage with a Buy rating. Report title |
| Royalty PharmaRPRX | U.S. | TD Cowen | Target Up | — | Buy | US$68.00 | US$80.00 | ReportDetailsRoyalty Pharma (RPRX) — TD Cowen raised its price target from $68.00 to $80.00, maintaining a Buy rating. Report title |
| SabreSABR | U.S. | Cantor Fitzgerald | Maintains | — | Neutral | — | US$2.00 | ReportDetailsSabre (SABR) — Cantor Fitzgerald reiterated its Neutral rating with a price target of $2.00. Report title |
| SalesforceCRM | U.S. | BTIG Research | Target Down | — | Buy | US$300.00 | US$250.00 | ReportDetailsSalesforce (CRM) — BTIG Research lowered its price target from $300.00 to $250.00, maintaining a Buy rating. Report title |
| Savaria Corp.SIS:CA | Canada | TD Securities | Maintains | — | Buy | — | C$38.00 | ReportDetailsSavaria Corp. (SIS:CA) — TD Securities maintained a Buy rating with a price target of C$38.00. Report title |
| SecuritizeSECZ | U.S. | B. Riley Financial | Initiates | — | Buy | — | US$14.00 | ReportDetailsSecuritize (SECZ) — B. Riley Financial initiated coverage with a Buy rating and a price target of $14.00. Report title |
| SecuritizeSECZ | U.S. | B. Riley Securities | Initiates | — | Buy | — | US$14.00 | ReportDetailsSecuritize (SECZ) — B. Riley Securities initiated coverage with a Buy rating and a price target of $14. Report title |
| ServiceTitanTTAN | U.S. | Piper Sandler | Maintains | — | Overweight | — | US$110.00 | ReportDetailsServiceTitan (TTAN) — Piper Sandler reiterated its Overweight rating with a price target of $110.00. Report title |
| Sherwin-WilliamsSHW | U.S. | Argus | Maintains | — | Buy | — | US$380.00 | ReportDetailsSherwin-Williams (SHW) — Argus reiterated its Buy rating with a price target of $380.00. Report title |
| Sienna Senior Living Inc.SIA:CA | Canada | Scotiabank | Maintains | — | Sector Outperform | — | C$26.00 | ReportDetailsSienna Senior Living Inc. (SIA:CA) — Scotiabank maintained a Sector Outperform rating with a price target of C$26.00. Report title |
| SimilarwebSMWB | U.S. | Barclays | Target Up | — | Overweight | US$11.00 | US$13.00 | ReportDetailsSimilarweb (SMWB) — Barclays raised its price target from $11.00 to $13.00, maintaining an Overweight rating. Report title |
| SinclairSBGI | U.S. | Guggenheim | Target Up | — | Buy | US$19.00 | US$20.00 | ReportDetailsSinclair (SBGI) — Guggenheim raised its price target from $19.00 to $20.00, maintaining a Buy rating. Report title |
| SKYX PlatformsSKYX | U.S. | Subscribe to MarketBeat All Access to unlock brokerage rankings | Target Down | — | Buy | US$2.50 | US$2.00 | ReportDetailsSKYX Platforms (SKYX) — Subscribe to MarketBeat All Access to unlock brokerage rankings lowered its price target from $2.50 to $2.00, maintaining a Buy rating. Report title |
| SLR InvestmentSLRC | U.S. | Keefe, Bruyette & Woods | Target Down | — | Market Perform | US$13.50 | US$13.00 | ReportDetailsSLR Investment (SLRC) — Keefe, Bruyette & Woods lowered its price target from $13.50 to $13.00, maintaining a Market Perform rating. Report title |
| SnowflakeSNOW | U.S. | UBS Group | Target Down | — | Buy | US$500.00 | US$450.00 | ReportDetailsSnowflake (SNOW) — UBS Group lowered its price target from $500.00 to $450.00, maintaining a Buy rating. Report title |
| Snowline Gold Corp.SGD:CA | Canada | CIBC | Maintains | — | Outperform | — | C$27.00 | ReportDetailsSnowline Gold Corp. (SGD:CA) — CIBC maintained an Outperform rating with a price target of C$27.00. Report title |
| SOLV EnergyMWH | U.S. | UBS | Upgrade | Neutral | Buy | — | US$37.00 | ReportDetailsSOLV Energy (MWH) — UBS upgraded the stock from Neutral to Buy, with a price target of $37. Report title |
| SOLV EnergyMWH | U.S. | UBS Group | Upgrade | Neutral | Buy | US$50.00 | US$37.00 | ReportDetailsSOLV Energy (MWH) — UBS Group upgraded the stock from Neutral to Buy and changed its price target from $50.00 to $37.00. Report title |
| SpireSR | U.S. | Mizuho | Target Up | — | Outperform | US$93.00 | US$96.00 | ReportDetailsSpire (SR) — Mizuho raised its price target from $93.00 to $96.00, maintaining an Outperform rating. Report title |
| Steel DynamicsSTLD | U.S. | Wells Fargo & Company | Target Up | — | Overweight | US$271.00 | US$285.00 | ReportDetailsSteel Dynamics (STLD) — Wells Fargo & Company raised its price target from $271.00 to $285.00, maintaining an Overweight rating. Report title |
| StrykerSYK | U.S. | BTIG Research | Target Up | — | Buy | US$304.00 | US$345.00 | ReportDetailsStryker (SYK) — BTIG Research raised its price target from $304.00 to $345.00, maintaining a Buy rating. Report title |
| Summit TherapeuticsSMMT | U.S. | Bernstein | Downgrade | Market Perform | Underperform | — | US$8.30 | ReportDetailsSummit Therapeutics (SMMT) — Bernstein downgraded the stock from Market Perform to Underperform, with a price target of $8.30. Report title |
| Summit TherapeuticsSMMT | U.S. | Sanford C. Bernstein | Downgrade | Market Perform | Underperform | US$11.90 | US$8.30 | ReportDetailsSummit Therapeutics (SMMT) — Sanford C. Bernstein downgraded the stock from Market Perform to Underperform and changed its price target from $11.90 to $8.30. Report title |
| Superior Plus Corp.SPB:CA | Canada | Stifel Nicolaus | Target Down | — | Buy | C$10.00 | C$8.50 | ReportDetailsSuperior Plus Corp. (SPB:CA) — Stifel Nicolaus lowered its price target from C$10.00 to C$8.50, maintaining a Buy rating. Report title |
| Tandem Diabetes CareTNDM | U.S. | Lake Street Capital | Initiates | — | Buy | — | — | ReportDetailsTandem Diabetes Care (TNDM) — Lake Street Capital initiated coverage with a Buy rating. Report title |
| Tandem Diabetes CareTNDM | U.S. | Piper Sandler | Initiates | — | Neutral | — | — | ReportDetailsTandem Diabetes Care (TNDM) — Piper Sandler initiated coverage with a Neutral ? Overweight rating. Report title |
| Tandem Diabetes CareTNDM | U.S. | Raymond James Financial | Upgrade | Market Perform | Strong-Buy | — | — | ReportDetailsTandem Diabetes Care (TNDM) — Raymond James Financial upgraded the stock from Market Perform to Strong-Buy. Report title |
| Tandem Diabetes CareTNDM | U.S. | Stifel Nicolaus | Upgrade | Hold | Buy | US$22.00 | US$26.00 | ReportDetailsTandem Diabetes Care (TNDM) — Stifel Nicolaus upgraded the stock from Hold to Buy and changed its price target from $22.00 to $26.00. Report title |
| Tandem Diabetes CareTNDM | U.S. | UBS Group | Upgrade | Neutral | Buy | — | — | ReportDetailsTandem Diabetes Care (TNDM) — UBS Group upgraded the stock from Neutral to Buy. Report title |
| Tencent Music Entertainment GroupTME | U.S. | Mizuho | Target Down | — | Outperform | US$15.00 | US$14.00 | ReportDetailsTencent Music Entertainment Group (TME) — Mizuho lowered its price target from $15.00 to $14.00, maintaining an Outperform rating. Report title |
| Transat A.T. Inc.TRZ:CA | Canada | CIBC | Target Down | — | Underperform | C$1.75 | C$1.50 | ReportDetailsTransat A.T. Inc. (TRZ:CA) — CIBC lowered its price target from C$1.75 to C$1.50, maintaining an Underperform rating. Report title |
| Transat A.T. Inc.TRZ:CA | Canada | National Bank | Target Down | — | Underperform | C$1.50 | C$1.15 | ReportDetailsTransat A.T. Inc. (TRZ:CA) — National Bank lowered its price target from C$1.50 to C$1.15, maintaining an Underperform rating. Report title |
| Tyler TechnologiesTYL | U.S. | TD Cowen | Target Up | — | Buy | US$450.00 | US$475.00 | ReportDetailsTyler Technologies (TYL) — TD Cowen raised its price target from $450.00 to $475.00, maintaining a Buy rating. Report title |
| Tyler TechnologiesTYL | U.S. | Truist Financial | Target Up | — | Buy | US$440.00 | US$500.00 | ReportDetailsTyler Technologies (TYL) — Truist Financial reiterated its Buy rating with its price target from $440.00 to $500.00. Report title |
| Tyson FoodsTSN | U.S. | Bank of America | Target Up | — | Neutral | US$56.00 | US$65.00 | ReportDetailsTyson Foods (TSN) — Bank of America raised its price target from $56.00 to $65.00, maintaining a Neutral rating. Report title |
| uniQureQURE | U.S. | HC Wainwright | Target Down | — | Buy | US$80.00 | US$65.00 | ReportDetailsuniQure (QURE) — HC Wainwright lowered its price target from $80.00 to $65.00, maintaining a Buy rating. Report title |
| United States AntimonyUAMY | U.S. | B. Riley Financial | Target Down | — | Buy | US$10.00 | US$6.00 | ReportDetailsUnited States Antimony (UAMY) — B. Riley Financial lowered its price target from $10.00 to $6.00, maintaining a Buy rating. Report title |
| VericelVCEL | U.S. | BTIG Research | Maintains | — | Neutral | — | — | ReportDetailsVericel (VCEL) — BTIG Research reiterated its Neutral rating. Report title |
| VeritoneVERI | U.S. | HC Wainwright | Initiates | — | Buy | — | US$2.00 | ReportDetailsVeritone (VERI) — HC Wainwright initiated coverage with a Buy rating and a price target of $2.00. Report title |
| VikingVIK | U.S. | Barclays | Target Up | — | Overweight | US$102.00 | US$111.00 | ReportDetailsViking (VIK) — Barclays raised its price target from $102.00 to $111.00, maintaining an Overweight rating. Report title |
| VikingVIK | U.S. | JPMorgan Chase & Co. | Target Down | — | Overweight | US$131.00 | US$122.00 | ReportDetailsViking (VIK) — JPMorgan Chase & Co. lowered its price target from $131.00 to $122.00, maintaining an Overweight rating. Report title |
| VikingVIK | U.S. | Morgan Stanley | Target Up | — | Equal Weight | US$92.00 | US$100.00 | ReportDetailsViking (VIK) — Morgan Stanley raised its price target from $92.00 to $100.00, maintaining an Equal Weight rating. Report title |
| VikingVIK | U.S. | Wells Fargo & Company | Target Up | — | Overweight | US$118.00 | US$120.00 | ReportDetailsViking (VIK) — Wells Fargo & Company raised its price target from $118.00 to $120.00, maintaining an Overweight rating. Report title |
| Vista EnergyVIST | U.S. | UBS Group | Target Up | — | Buy | US$80.00 | US$100.00 | ReportDetailsVista Energy (VIST) — UBS Group raised its price target from $80.00 to $100.00, maintaining a Buy rating. Report title |
| Vital Infrastructure Property TrustVITL.UN:CA | Canada | RBC | Target Down | — | Sector Perform | C$6.00 | C$5.50 | ReportDetailsVital Infrastructure Property Trust (VITL.UN:CA) — RBC lowered its price target from C$6.00 to C$5.50, maintaining a Sector Perform rating. Report title |
| VolitionRxVNRX | U.S. | Freedom Broker | Downgrade | Buy | Hold | — | — | ReportDetailsVolitionRx (VNRX) — Freedom Broker downgraded the stock from Buy to Hold. Report title |
| Walt DisneyDIS | U.S. | Bank of America | Target Up | — | Buy | US$125.00 | US$135.00 | ReportDetailsWalt Disney (DIS) — Bank of America raised its price target from $125.00 to $135.00, maintaining a Buy rating. Report title |
| Walt DisneyDIS | U.S. | Barclays | Target Up | — | Overweight | US$115.00 | US$135.00 | ReportDetailsWalt Disney (DIS) — Barclays raised its price target from $115.00 to $135.00, maintaining an Overweight rating. Report title |
| Walt DisneyDIS | U.S. | Guggenheim | Target Up | — | Buy | US$120.00 | US$135.00 | ReportDetailsWalt Disney (DIS) — Guggenheim raised its price target from $120.00 to $135.00, maintaining a Buy rating. Report title |
| Walt DisneyDIS | U.S. | JPMorgan Chase & Co. | Target Up | — | Overweight | US$137.00 | US$140.00 | ReportDetailsWalt Disney (DIS) — JPMorgan Chase & Co. raised its price target from $137.00 to $140.00, maintaining an Overweight rating. Report title |
| Walt DisneyDIS | U.S. | Needham & Company LLC | Target Up | — | Buy | US$125.00 | US$135.00 | ReportDetailsWalt Disney (DIS) — Needham & Company LLC raised its price target from $125.00 to $135.00, maintaining a Buy rating. Report title |
| Walt DisneyDIS | U.S. | Raymond James Financial | Maintains | — | Outperform | — | US$133.00 | ReportDetailsWalt Disney (DIS) — Raymond James Financial reiterated its Outperform rating with a price target of $133.00. Report title |
| Walt DisneyDIS | U.S. | Rosenblatt Securities | Target Up | — | Buy | US$126.00 | US$141.00 | ReportDetailsWalt Disney (DIS) — Rosenblatt Securities raised its price target from $126.00 to $141.00, maintaining a Buy rating. Report title |
| Walt DisneyDIS | U.S. | Wells Fargo & Company | Target Up | — | Overweight | US$132.00 | US$140.00 | ReportDetailsWalt Disney (DIS) — Wells Fargo & Company raised its price target from $132.00 to $140.00, maintaining an Overweight rating. Report title |
| XPENGXPEV | U.S. | Barclays | Target Down | — | Underweight | US$14.00 | US$12.00 | ReportDetailsXPENG (XPEV) — Barclays lowered its price target from $14.00 to $12.00, maintaining an Underweight rating. Report title |
| Xtract One Technologies Inc.XTRA:CA | Canada | Ventum Financial | Maintains | — | Buy | — | C$1.15 | ReportDetailsXtract One Technologies Inc. (XTRA:CA) — Ventum Financial maintained a Buy rating with a price target of C$1.15. Report title |
| York Space SystemsYSS | U.S. | Barclays | Target Down | — | Equal Weight | US$11.00 | US$5.00 | ReportDetailsYork Space Systems (YSS) — Barclays lowered its price target from $11.00 to $5.00, maintaining an Equal Weight rating. Report title |
| Zoom CommunicationsZM | U.S. | BTIG Research | Target Down | — | Buy | US$125.00 | US$115.00 | ReportDetailsZoom Communications (ZM) — BTIG Research lowered its price target from $125.00 to $115.00, maintaining a Buy rating. Report title |
| Zoom CommunicationsZM | U.S. | Rosenblatt Securities | Maintains | — | Buy | — | US$130.00 | ReportDetailsZoom Communications (ZM) — Rosenblatt Securities reiterated its Buy rating with a price target of $130.00. Report title |
| ZoomInfo TechnologiesGTM | U.S. | Morgan Stanley | Target Down | — | Equal Weight | US$5.00 | US$4.00 | ReportDetailsZoomInfo Technologies (GTM) — Morgan Stanley lowered its price target from $5.00 to $4.00, maintaining an Equal Weight rating. Report title |
No matching calls. Try another date, market or search.
Report date: 2026-11-18 · Dates use America/New_York. Automatically reflects published daily analyst reports. Coverage is limited to recognizable entries in those reports; missing fields appear as —. Targets retain the currency stated in the report. Exact duplicate calls are removed; different analysts and materially different updates remain separate. Summary counts cover the selected date before filtering.
Source reports for this date
American Analyst Ratings Updates — November 18, 2026
Canadian Analyst Ratings Updates — November 18, 2026
Available date history comes from the latest 300 matching analyst articles. Analyst ratings and targets are estimates, not guaranteed outcomes.